Stay updated on market trends for SLN. Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback